Abstract
A novel mechanistic model describing the rate of COVID-19 spread is presented, that differs conceptually from previously published deterministic models. One of its main characteristics is that the pool of infected people is not assumed to be homogeneously mixed, but rather as a passage into which individuals enter upon contagion, move within it in a plug-flow manner and leave at recovery, within a fixed time period. So, the present model differs conceptually in the way it describes the dynamics of infection. An ‘infection unit’ is defined as the amount of COVID-19 virus that generates contagion, if it reaches a susceptible individual. This model separately considers various pools: symptomatic and asymptomatic infected patients; three different pools of recovered individuals; pools of assisted, hospitalized patients; the quarantined and, finally, those who died from COVID-19. The transmission of the disease from an infected person to others is described by an infection rate function, while an encounter frequency function modulates the frequency of effective encounters between the infected and the susceptible. The influence of the model’s parameters on the predicted results is presented. The effect of social restrictions and of quarantine policy on pandemic spread is shown. For model calibration, a set of experimental data is used. The model enables the calculation of the actual behaviour of the studied pools during pandemic spread.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
None
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
-
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.